Amphastar Pharmaceuticals Stock Price and Value Analysis

Amphastar Pharmaceuticals (NasdaqGS:AMPH) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Amphastar Pharmaceuticals to reach your target.

Target type

AMPH Free Cash Flow Trend

Free Cash Flow trendline for AMPH
Free Cash Flow trendline for Amphastar Pharmaceuticals
CSV

Based on historical returns, we believe that Amphastar Pharmaceuticals can grow its free cash at a rate of about 4%. That's positive!

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company is making money at a modest rate.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company pays no dividend.

Inside the AMPH Numbers

AMPH Price
(Amphastar Pharmaceuticals stock price per share)
$28.11
[?] AMPH Fair Price
(based on intrinsic value)
$14.27
[?] AMPH Safety Price (based on a variable margin of safety) $8.56
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 32% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Drug Manufacturers - General stocks
[?] Cash Yield 0.84%
[?] Free Cash Flow Jitter 72%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 4,261,462 shares shorted. With 31,409,473 shares available for purchase and an average trading volume over the past 10 trading days of 528,450, it would take at least 8.1 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2012 1297184 -24.8
2013 1297184 10.7
2014 1297184 0.6
2015 1297184 -8.6
2016 1297184 18.8
2017 1297184 17.1
2018 1297184 10.2
2019 1297184 9.6
2020 1297184 21.5
2021 1297184 61
2022 1297184 54.4
2023 1297184 150
2024 1297184 180
2025 1297184 123

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 11 fiscal years from 2012 to 2025 with positive net income, operating cash flow totaled $946 million against net income of $642 million, or 1.47 times. Net income was negative in 3 of the 14 years, and those years are left out of the ratio.

In 2025, operating cash flow was 1.59 times net income, compared with 0.98 times for the earliest three years (2012 to 2014).

In 2025, capital expenditures were $34.9 million, 22.3% of operating cash flow of $156 million, which leaves an estimated $121 million after capex. Across the 13 years with reported capex, it averaged 39.1% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2012 18.1 -1.6 23.1 -0.09
2013 11.9 31 17.6 2.62
2014 -10.7 21.1 20.5 n/a
2015 -2.8 10.7 16 n/a
2016 9.8 38.6 21.4 3.93
2017 3.6 39.2 35.1 10.75
2018 -5.7 38.2 46.8 n/a
2019 48.9 41.8 41.6 0.85
2020 1.4 57.3 33.9 40.82
2021 62.1 98 27.5 1.58
2022 91.4 89.2 24 0.98
2023 138 184 38.2 1.33
2024 160 213 41 1.34
2025 98.1 156 34.9 1.59

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $647 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $400 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $75.6 million, 61.5% of estimated free cash flow of $123 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 18.8 n/a 9.9 9.9 52.6%
2017 17.1 n/a 30.7 30.7 180.0%
2018 10.2 n/a 25 25 244.7%
2019 9.6 n/a 22.3 22.3 232.3%
2020 21.5 n/a 24.4 24.4 113.5%
2021 61 n/a 28.9 28.9 47.3%
2022 54.4 n/a 39.9 39.9 73.3%
2023 150 n/a 58.1 58.1 38.6%
2024 180 n/a 85.5 85.5 47.4%
2025 123 n/a 75.6 75.6 61.5%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $204 million in 2012 and $720 million in 2025, a compound annual growth rate of 10.2% over 13 years.

Revenue fell 1.7% from 2024 to 2025.

Our estimated free cash flow was $123 million in 2025, 17.1% of revenue. In 2012 the estimated margin was negative 12.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2012 204 -24.8 -12.1%
2013 230 10.7 4.6%
2014 210 0.6 0.3%
2015 252 -8.6 -3.4%
2016 255 18.8 7.4%
2017 240 17.1 7.1%
2018 295 10.2 3.5%
2019 322 9.6 3.0%
2020 350 21.5 6.2%
2021 438 61 13.9%
2022 499 54.4 10.9%
2023 644 150 23.4%
2024 732 180 24.7%
2025 720 123 17.1%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $170 million against total liabilities of $840 million, or 20.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 51.6% of total assets in 2025, compared with 25.7% in 2013, an increase of 25.8 percentage points.

Stockholders equity was $789 million in 2025, compared with $252 million in 2013, a rise of 213.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 9.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2013 339 53.6 87.2 252
2014 389 67.8 108 282
2015 390 66.1 96.6 296
2016 428 72.4 101 329
2017 451 65.6 117 334
2018 514 86.3 149 364
2019 587 73.7 159 428
2020 631 92.6 183 449
2021 672 126 226 446
2022 742 156 213 529
2023 1,513 144 873 639
2024 1,577 152 845 732
2025 1,629 170 840 789

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $28.11, our model's value equals that price if free cash flow grows an average of 25.0 percent a year over the 10 projection years. Our model assumes 4.1 percent a year for this stock, so the price implies growth of 25.0 percent, which is above the 4.1 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

At 25.0 percent a year, free cash flow would grow about 9.3 times over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $10.7 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $22.49 19.7%
Current price $28.11 25.0%
20 percent above the current price $33.73 28.9%
Our model (stored fair price) $14.27 4.1%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Amphastar Pharmaceuticals reported positive free cash flow in 12 of the 14 fiscal years we have from its current SEC filer.

Our fair value estimate for Amphastar Pharmaceuticals is $14.27, below its current price of $28.11.

Free cash flow is volatile from year to year, with a variability measure of 72%.

No dividend yield is recorded for Amphastar Pharmaceuticals in our data.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 32% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Amphastar Pharmaceuticals, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Amphastar Pharmaceuticals (AMPH) 1,199 12.9 - 0.8% 97% above
Innoviva (INVA) 1,309 7.8 - - 12% above
Phibro Animal Health Corporation (PAHC) 1,384 13.6 1.3% - 87% above
ANI Pharmaceuticals (ANIP) 1,571 14.0 - - 190% above
Collegium Pharmaceutical (COLL) 783 23.1 - - 160% above
SIGA Technologies (SIGA) 190 265.0 - 7.1% 86% below
Perrigo Company plc (PRGO) 2,226 - 6.8% 68.6% 91% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1297184.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 2 of the 14 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-19
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: AMPH annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in AMPH

Does Amphastar Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: AMPH

This example shows how we apply the Trendshare checklist to AMPH: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 28.11
    • Market cap: $1.2B
    • EPS: 2.18
  2. Step 2 — Valuation checks

    • P/E: 12.894
    • FCF yield: 0.9%
    • Date checked: Nov 19, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.